China Medical System Holdings Ltd (CMS, HKG: 0867) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for two of its drug candidates: CMS-D001 and CMS-D002.
CMS-D001 is a highly selective TYK2 (tyrosine kinase 2) inhibitor aimed at treating immune inflammatory diseases, including psoriasis, atopic dermatitis, and systemic lupus erythematosus (SLE). The clinical trial will evaluate the drug’s safety, tolerability, pharmacokinetics, and efficacy in both healthy subjects and patients with plaque psoriasis.
Meanwhile, CMS-D002 is a small-molecule gonadotropin-releasing hormone (GnRH) receptor antagonist being developed for conditions such as endometriosis, uterine fibroids, and prostate cancer. This candidate will undergo similar assessments for safety, tolerability, pharmacokinetics, and efficacy in healthy premenopausal female subjects.- Flcube.com
